Sangviritrin - instructions for use, doses, side effects, contraindications, price, where to buy

Sanguiritrin®

Externally, locally apply a 0.2% alcohol solution. An aqueous-alcohol solution prepared ex tempore from a 0.2% alcohol solution is also used. To do this, the drug is diluted 40 times (1 teaspoon per 200 ml of water).

As a preventative measure, newborns are treated with skin folds using a sterile cotton swab moistened with a 0.2% alcohol solution of the drug or an aqueous alcohol solution prepared from it daily, 2 times a day during the first 5-6 days of life. To prevent purulent-inflammatory complications, the wound is treated with a sterile gauze swab, generously moistened with a 0.2% alcohol solution of the drug, covered with a sterile napkin moistened with the same solution, and a fixing bandage is applied. After 3-4 days, the wound is re-treated with the drug and a dry sterile bandage is applied. The course of treatment is 7-10 days.

Treatment of periodontitis is carried out after removing dental plaque and curettage of pathological gum pockets. Thin turundas, generously moistened with a 0.2% alcohol solution of the drug or an aqueous-alcohol solution prepared immediately before use, are injected into the gum pockets for 20 minutes. The procedure is carried out daily or every other day. The course of treatment is 4-6 procedures.

For stomatitis of various etiologies, an aqueous-alcohol solution of the drug prepared from a 0.2% alcohol solution of the drug is applied to the lesions of the oral mucosa 2-3 times a day for 2-5 days. Children over 5 years old with stomatitis are prescribed rinsing with a warm aqueous-alcohol solution of the drug. For children under 5 years of age with stomatitis, the oral mucosa is lubricated with an aqueous-alcohol solution of the drug.

For tonsillitis, the tonsils are treated with a 0.2% alcohol solution of the drug once a day for 2-5 days. In addition, adults and children over 5 years of age are prescribed rinsing with an aqueous-alcohol solution daily 3-5 times a day for 3-7 days.

Treatment for external otitis is carried out after careful removal of discharge from the external auditory canal and the introduction of cotton wool moistened with a 0.2% alcohol solution of the drug for 10-15 minutes 2-3 times a day. The minimum course of treatment is 7 days.

In the treatment of chronic purulent otitis after removing pus from the ear, a 0.2% alcohol solution of the drug is instilled into the ear of adults, 8 drops 3 times a day, for children - 3-4 drops 3 times a day. The course of treatment is 14 days.

For the treatment of infected burns, long-term non-healing wounds and ulcers, the lesions are treated with a sterile gauze swab, abundantly moistened with a 0.2% alcohol solution of the drug, covered with a sterile napkin moistened with the same solution, and a fixing bandage is applied. For infected burns, dressings are performed every other day, for long-term non-healing wounds and ulcers - daily 1-2 times a day. The duration of treatment depends on the nature and severity of the disease. The minimum course of treatment is 10-12 days.

For endocervicitis, colpitis, vaginitis, cervical erosion, Sangviritrin® is used as douching or lotions with a warm aqueous-alcohol solution 1-2 times a day. The course of treatment is 5-10 procedures.

For pyoderma, dermatomycosis, including those complicated by mixed microflora, the drug is prescribed in the form of bandages soaked in a 0.2% alcohol solution of the drug 1-2 times a day. The duration of treatment is up to 3 weeks.

Sangviritrin solution for external and local use 0.2% 50 ml bottle 1 pc. in St. Petersburg

Sangviritrin®

Inside,

(without chewing) after eating.

Adults are usually prescribed 2 tablets. (10 mg) 3-4 times a day (if necessary, the daily dose can be increased to 9 tablets), children 10-15 years old - (5-10 mg) 1-2 tablets. 3 times a day (maximum daily dose - up to 6 tablets); 5–10 years - 1 tablet (5 mg) 3-4 times a day (maximum daily dose - up to 4 tablets); 3–5 years - 1 tablet (5 mg) 2-3 times a day (maximum daily dose - up to 3 tablets).

The duration of the course of treatment depends on the nosological form and severity of the disease and is on average: for acute intestinal infections (dysentery, salmonellosis, foodborne illnesses) - 5–7 days (up to 10 days if necessary); for dysbacteriosis - up to 10–14 days; in case of bacterial carriage (bacterial excretion) - 7–14 days; for pharyngomycosis and candidiasis - up to 14 days; for microsporia - 4–5 weeks.

Repeated courses of treatment are possible on the recommendation of a doctor.

Alcohol solution. Externally, locally

A 0.2% aqueous-alcohol solution is used to treat skin folds in newborns daily (2 times a day in the first 5–6 days of life) using a sterile cotton swab.

Treatment of periodontitis is carried out after removing dental plaque and curettage of pathological gum pockets. Thin turundas, generously moistened with the drug or its aqueous solution, are inserted into the gum pockets for 20 minutes. An aqueous solution of the drug is prepared immediately before use. To prepare an aqueous solution, the drug is diluted 40 times (1 teaspoon per 200 ml of warm boiled water). The procedure is repeated daily or every other day. The course of treatment is 4–6 procedures. For stomatitis of various etiologies, solutions of the drug are applied to lesions of the oral mucosa 2-3 times a day for 2-5 days. Children over 5 years old are prescribed rinsing with a warm aqueous solution of the drug; under 5 years of age, for stomatitis, the oral mucosa is lubricated with an aqueous solution of the drug.

For tonsillitis, the tonsils are treated with the drug once a day for 2–5 days. In addition, adults and children over 5 years of age are prescribed rinsing with a warm aqueous solution of the drug daily 3–5 times a day. For children under 5 years old, lubricate the oral mucosa with this solution 3-4 times a day. The duration of treatment is 3–7 days.

For external otitis, turundas moistened with the drug are inserted into the ear canal for 10–15 minutes, 2–3 times a day. The minimum course of treatment is 2 weeks. For chronic purulent otitis media, the drug is instilled into adults 5–8 drops, for children 1–2 drops 3–4 times a day.

To prevent purulent-inflammatory complications, the wound is treated daily with a sterile gauze swab, generously moistened with the drug, covered with a sterile napkin moistened with the same solution, and a fixing bandage is applied. After 3-4 days, the wound is re-treated with the drug and a dry sterile bandage is applied. The course is determined by the period of wound healing; in uncomplicated cases, the period of use is 7–10 days.

For the treatment of infected burns, long-term non-healing wounds and ulcers, open infected fractures, an aqueous solution of the drug is used. Wounds and ulcers are washed with an aqueous solution of the drug, and bandages with the solution are applied to the wound surface. For infected burns, dressings are performed every other day, for other wounds - daily 1-2 times a day. The duration of treatment depends on the nature and severity of the disease.

For endocervicitis, colpitis, vaginitis, cervical erosions, douching, irrigation and lotions with a warm aqueous solution of the drug are performed daily 1-2 times a day. The course of treatment is 5–10 procedures.

For pyoderma, superficial blastomycosis and dermatomycosis, incl. complicated by mixed flora, the drug is prescribed in the form of dressings or lubrication of the lesion daily 1-2 times a day. The duration of treatment is determined by the nature and severity of the disease.

Sangviritrin® liniment 0.5%

Liniment. Locally, externally.

The drug is used in children and adults.

For stomatitis of various etiologies, the drug is applied to lesions of the oral mucosa 2-3 times a day for 2-5 days.

For long-term non-healing wounds and ulcers, dressings with the drug are performed daily or every 1–2 days. The duration of treatment depends on the nature and severity of the disease.

For endocervicitis, colpitis, vaginitis, cervical erosions, the drug is applied to the vaginal walls and cervix daily or every other day (the drug is applied on an outpatient basis). The course of treatment is 3–4 weeks.

For pyoderma, superficial blastomycosis and dermatomycosis, incl. complicated by mixed flora, the drug is prescribed in the form of bandages or lubrication of the lesion daily 1-2 times a day. The course of treatment is 8–10 days. If necessary, as prescribed by a doctor, the course of treatment can be continued.

For newborns and young children with pustular skin diseases, apply the drug 1-2 times a day for 5-8 days, for diaper rash and abrasions of the skin - for 1-3 days.

Results of a clinical study of an antimicrobial herbal preparation

The last 50 years of the outgoing century have been marked by major advances in the treatment of diseases caused by various infectious agents. Such achievements include the creation of antibiotics and synthetic chemotherapeutic agents that act on pathogenic pathogens. However, the constant and widespread (and not always justified) use of antibiotics and synthetic chemotherapeutic agents leads to a number of phenomena that complicate the possibility of their rational use:

the occurrence of allergic reactions when using most antibiotics and, as a consequence, allergization of the population, especially children;
the presence of serious side (toxic) effects on systems and organs;
development of drug resistance of microorganisms to known antimicrobial agents;
disruption of the normal composition of microflora, leading to an expansion of the spectrum of pathogenic microflora due to microorganisms previously classified as opportunistic, and the emergence of new infectious processes (dysbacteriosis, bacterial carriage and release of pathogenic pathogens into the environment).

Therefore, the development of original antimicrobial agents of a different nature - with new properties and a different mechanism of action - is so urgent.

Research carried out at the VILAR Institute has made it possible to identify a number of plants that are promising for the creation of effective medicinal preparations, one of which is Sanguiritrine [1, 2], which is a mixture of bisulfates of two quaternary benzo[c]phenanthridine alkaloids, sanguinarine and chelerythrine, which are similar in structure and properties.

In in vitro experiments, Sangviritrin was studied on 111 strains of microorganisms. Most of them were isolated from patients with different nosological forms of diseases with mono- or polyresistance to widely used antibiotics (tetracycline, claforan, polymyxin, kanamycin, rifampicin, doxycycline, cefazol, carbenicillin, erythromycin, oleandomycin, kefzol, erythromycin, chloramphenicol, gentamicin, lincomycin, amikacin, etc.) [3].

It was found that Sangviritrin inhibits the growth and development of a wide range of microorganisms, including clinical strains with a high degree of drug resistance, including: bacteria of the genus Staphylococcus, Streptococcus, Proteus, Pseudomonas, Salmonella, Shigella, Escherichia, Enterobacter, Acinetobacter, Serratia, pathogenic protozoa of the genus Trichomonas and Entamoeba, pathogenic fungi of the genus Candida, Trichophyton, Microsporum, etc., including pathogens of deep mycoses (Nocardia, Cryptococcus, Actinomyces).

Pharmacological properties

Sangviritrin has a wide spectrum of antimicrobial activity, inhibiting the development of gram-positive and gram-negative bacteria, yeast-like and filamentous fungi, and pathogenic protozoa. Sangviritrin is active against antibiotic-resistant strains of microorganisms. In therapeutic doses, Sangviritrin acts bacteriostatically [5–7]. The mechanism of the antimicrobial action of Sangviritrin is based on the suppression of bacterial nuclease, disruption of the processes of permeability of cell walls, division septa, and the structure of the nucleoid [3].

In the course of toxicological studies, it was established that Sangviritrin is a moderately toxic substance. The drug has no cumulative properties, it does not have mutagenic, teratogenic or carcinogenic effects. Sangviritrin has a pronounced immunostimulating effect on the humoral and cellular components of immunity. The drug has no local irritant or general toxic properties, including when tested on newborns and developing organisms [8].

Clinical studies of Sangviritrin

Clinical studies of Sangviritrin as an external antimicrobial agent were conducted in 15 leading clinical institutions. Three dosage forms were studied: 0.2% aqueous-alcohol solution (hereinafter referred to as 0.2% solution), 1% liniment, and 0.001–0.1% aqueous solutions prepared ex tempore.

The medicinal properties were studied in 7506 patients: 6520 children (including 6186 newborns and young children) and 986 adult patients (including 678 pregnant women). The effectiveness of the drug is shown in Fig. 1.

The effectiveness and tolerability of Sangviritrin enteric tablets as an antimicrobial agent with general resorptive action was studied in five medical institutions in 430 patients (207 adult patients aged 15 to 85 years and 223 children aged one to 14 years). The study showed that Sangviritrin in the form of enteric-coated tablets, when taken orally in therapeutic doses, is well tolerated in children and adults, does not cause local or general negative effects, does not lead to allergization and other side effects.

Application of Sangviritrin solution

Studies of Sangviritrin solution in ENT pathologies (external diffuse otitis, chronic purulent otitis media, chronic purulent epitympanitis and mesotympanitis, otomycosis, tonsillitis, acute pharyngitis, chronic tonsillitis, etc.) were carried out in 255 patients, including 40 children aged from 4 months to 14 years (Moscow Research Institute of Ear, Nose and Throat, Children's City Clinical Hospital No. 9 named after G. N. Speransky, Department of ENT Diseases, Institute of Pediatrics, St. Petersburg). The use of a 0.2% solution 2-3 times a day (3-5 drops or in the form of turundas moistened with a solution, administered for 5-10 minutes) for 7-14 days led to a decrease and cessation of suppuration from the ear in most patients , improvement of the otoscopic picture and epidermization after surgical interventions on the ear [9, 10].

For tonsillitis, the tonsils were treated with a 0.2% aqueous-alcohol solution of Sanguiritrin once a day for 2–5 days. In addition, adults and children over 5 years of age were prescribed rinsing with a 0.005% solution daily 3–5 times a day for 3–7 days.

When sanitizing the maxillary sinuses with a 0.01% aqueous solution of Sangviritrin, a positive effect was also obtained (although the irritant effect and bitter taste of the drug were noted).

The use of enteric-soluble tablets Sangviritrin in children with ENT pathologies

The high effectiveness of Sangviritrin enteric tablets in the treatment of purulent-inflammatory diseases complicated by dysbacteriosis and bacterial carriage was shown in a study of the drug in 110 children aged from one to 15 years with pathology of the ENT organs (Children's City Clinical Hospital No. 9 named after G. N. Speransky ). In all patients, the purulent-inflammatory process was confirmed by bacteriological examination (the presence of pathogenic bacteria in acute and chronic purulent processes and pathogenic fungi in pharyngomycosis). The study found that Sangviritrin enteric tablets not only have a positive effect on the clinical course of purulent-inflammatory diseases of the ENT organs in children, but also contribute to the normalization of the microflora accompanying these diseases, prevent the development of convalescent bacterial carriage and have a normalizing effect on the microflora in dysbiosis , often complicating the course of ENT diseases in pediatric patients (Fig. 2).

Use of Sangviritrin in surgery

A positive result was obtained with the use of Sangviritrin in 207 surgical patients, including 185 with cardiac surgery (of which 99 were operated on under artificial circulation) aged from 25 to 73 years and in 22 patients with long-term non-healing ulcers and wounds. The wounds were treated with a 0.2% solution of the drug, followed by the application of a gauze pad soaked in a 0.2% solution once every 1–2 days (4–5 treatments in total); the sutures were removed on days 8–11. The drug was shown to be highly effective: regeneration and healing of wounds were accelerated, the inoculation of microorganisms from wound discharge sharply decreased, and resistance of microorganisms did not develop. For long-term non-healing purulent ulcers and wounds, the best effect (complete healing, wound cleansing, appearance of epithelization) was achieved with the simultaneous use of both dosage forms of Sanguiritrin (treatment of the wound with a 0.2% solution followed by application of a bandage with 1% liniment) [11, 12].

Thus, in all clinical institutions, when using Sangviritrin, not only its high effectiveness was noted, but also good tolerability in the studied dosage forms, the absence of general toxic and locally irritating properties. Only weeping eczema is noted as a contraindication in dermatology.

Among the positive qualities of the drug, the absence of the development of resistance to it, even with long-term use, and a wide range of antimicrobial activity, including against mono- and multi-resistant strains of microorganisms, are noted [13].

Thus, according to leading Russian clinics, Sangviritrin is one of the effective modern antimicrobial agents with local and general resorptive action for the prevention and treatment of various infectious diseases [14–17].

Sangviritrin is used as an external agent in the form of solutions: in neonatology (for preventive treatment of the skin of newborns and treatment of pustular skin lesions); in surgery (for the healing of surgical wounds, including in patients with artificially reduced immunity, infected burns, long-term non-healing wounds and ulcers), dentistry (for periodontitis, ulcerative necrotic stomatitis), otorhinolaryngology (for sore throat, otitis), dermatology (for pyodermatitis, dermatomycosis, etc.), in gynecology (for colpitis, vaginitis, endocervicitis, cervical erosion). As a general resorptive agent in the form of enteric tablets: for acute intestinal infections (dysentery, salmonellosis, food toxic infections); wound infections and various infectious complications caused by pathogenic microflora (convalescent bacterial carriage); diseases associated with disruption of normal microflora (dysbacteriosis); diseases caused by pathogenic fungi (pharyngomycosis, candidiasis, microsporia, etc.).

The main advantages of Sangviritrin:

good tolerance;
lack of allergenic, mutagenic, teratogenic and local irritating properties;
can be used in newborns and pregnant women;
characterized by a wide spectrum of antimicrobial action;
effective against mono- and multi-antibiotic-resistant strains of microorganisms;
Microorganisms do not develop resistance to Sanviritrin.

Literature

Vichkanova S. A. Inhibitors of microorganisms among natural substances of plant origin: abstract of thesis. dis. doc. honey. Sci. M., 1981. 48 p.
Bykov V. A., Vichkanova S. A., Glyzin V. I., Klimakhin G. I. Efficiency of use and prospects for the development of drugs based on Sangviritrin. III Ross. national congr. "Man and Medicine." Abstract. report M., 1996. P. 12.
Bykov A. S., Vichkanova S. A., Seleznev A. S. et al. Electron microscopic study of the effect of Sangviritrin on microorganisms in in vitro experiments // Antibiotics. 1983; 6:421–424.
Vichkanova S. A. Search for new chemotherapeutic agents from higher plants // Herba pol. 1970; 16 (3): 301–308.
Vichkanova S. A. Prospects for searching for new chemotherapeutic drugs from higher plants. Materials of the All-Union. scientific conf. according to Pharmacol. and wedge. study of medicinal preparations from plants. M., 1972; 194–203.
Vichkanova S. A. Results and prospects of the work of the All-Union Scientific Research Institute of Medicinal Plants to find new chemotherapeutic properties of plant origin. Phytoncides. Kyiv, 1975. pp. 89–93.
Vichkanova S. A. Prospects for the search for microbial inhibitors among natural substances from higher plants. Sat. scientific works of VILAR “The state and prospects of research into biologically active substances from plants and the creation of new drugs based on them.” M., 1983: 107–118.
Bortnikova V.V. Comparative toxicological characteristics and new pharmacological properties of antimicrobial and antiviral drugs of plant origin: abstract. dis. Ph.D. biol. Sci. Kupavna, 1988. P. 13.
Kunelskaya V. Ya. On the use of Sanguinarine for fungal diseases of the ear // Journal. ear, nose and throat diseases. 1969; 5: 101–103.
Kunelskaya V. Ya. Use of the drug Sanguinarine in the treatment of chronic otitis media and external otitis. Pharmacology and chemotherapy. M.: Kolos, 1971. pp. 266–269.
Vichkanova S. A., Gabrielyan N. I., Chubarova A. V., et al. The use of Sanviritrin for the prevention of wound infection in cardiac surgery patients. Abstract. report VIII Ross. national congr. "Man and Medicine." M., 2001. P. 221.
Zaytsev G.P. Use of Sanguinarine in patients with purulent wounds and trophic ulcers. Pharmacology and chemotherapy. M.: Kolos, 1971. pp. 261–262.
Vichkanova S.A. Sangviritrin is an antimicrobial drug from plants of the genus Macleaja. In the book: Development and implementation of new methods and means of traditional medicine. Kiseleva T. L. et al. M.: Scientific and practical. center of tradition honey. and homeopathy, Ministry of Health of the Russian Federation, 2001. 370 p.
Vichkanova S. A., Rostotsky B. K. et al. Medicine. A. s. No. 230387 (USSR) - Inventions. 1968. No. 34.
Vichkanova S. A., Tolkachev O. N., Martynova R. G. et al. Sangviritrin is a new medicinal herbal preparation with antimicrobial action // Chemical-Pharmaceutical Journal. 1982; 16 (12): 107–112.
Bykov V. A., Vichkanova S. A., Glyzin V. I., Klimakhin G. I. Efficiency of use and prospects for the development of drugs based on sanviritrin // III Ros. National congr. "Man and Medicine." Abstract. report M., 1996, p. 12.
State register of medicines, 2000.

S. A. Vichkanova, Doctor of Medical Sciences, Professor

All-Russian Institute of Medicinal and Aromatic Plants, Moscow

Contact information about the author for correspondence

Sangviritrin (tablets), 30 pcs., 5 mg, enteric tablets

Sangviritrin®

Inside,

(without chewing) after eating.

Indications

As a prophylactic agent: for newborns to prevent purulent-inflammatory skin diseases and for surgical patients - to prevent wound infections.

As a remedy: for infectious and inflammatory diseases of the skin and mucous membranes of bacterial and fungal etiology, including Candida albicans; in dentistry - for periodontitis, stomatitis, ulcerative necrotic gingivostomatitis and other lesions of the oral mucosa; in otolaryngology - for sore throat, diseases of the middle ear and external auditory canal; in surgery - for infected burns, wounds that do not heal for a long time and ulcers; in gynecology - for endocervicitis, colpitis, vaginitis, cervical erosion; in dermatology - for pyoderma, superficial blastomycosis, dermatomycosis.

Clinical use of Sangviritrin for dysbacteriosis

Sangviritrin, obtained from the herb Macleaia cordata and Macleaia parctifidae of the poppy family, is a natural sum of the bisulfates of the alkaloids sanguinarine and chelerythrine. Sangviritrin has a wide spectrum of antimicrobial activity, providing an inhibitory effect against clinical strains of pathogenic microorganisms, including gram-positive and gram-negative bacteria (genus Staphylococcus, Streptococcus, Enterococcus, Shigella, Escherichia, Salmonella, Proteus, Acinetobacter, Citrobacter, Pseudomonas, Serratia, Klebsiella, Antracoides, Cryptococcus), pathogenic fungi (yeast-like fungi of the genus Candida, pathogens of zoonotic infections of the genus Microsporum, Trichophyton, Aspergillus, etc.), as well as Actinomyces and parasitic protozoa of the genus Trichomonas and Entamoeba (Table 1). A feature of the antimicrobial effect is the manifestation of activity against mono- and multi-resistant strains of pathogenic microorganisms. In therapeutic doses, the effect of the drug is bacteriostatic, to the greatest extent in an alkaline and slightly alkaline environment, which is important for the manifestation of the drug’s activity in the intestines. The mechanism of the antimicrobial action of Sangviritrin is based on the suppression of bacterial nuclease, disruption of the processes of permeability of cell walls, division septa, and nucleoid structure. A characteristic feature of Sangviritrin is the absence of the development of drug resistance of microorganisms to the drug [2–7]. In medical practice, Sangviritrin was previously approved for external use as an antimicrobial agent in the form of liniment and aqueous-alcoholic solution [8]. Enteric-soluble tablets of Sangviritrin were developed to create a drug with general resorptive action for oral use [8,9]. The purpose of the clinical studies was to study the effectiveness and safety of Sanguiritrin in the dosage form “enteric tablets” [10]. The drug for clinical trials was sent to the Department of Infectious Diseases of the Russian Medical Academy of Postgraduate Education, the Department of Skin Diseases of the Russian State Medical University, the intestinal diagnostic department and the 2nd ENT department of Children's City Clinical Hospital No. 9 named after. G.N. Speransky, Research Institute of Transplantology and Artificial Organs of the Ministry of Health of the Russian Federation. The safety and effectiveness of Sangviritrin enteric tablets were studied in 430 patients, including 207 adults and 223 pediatric patients. Sangviritrin tablets 0.005 g with enteric coating were prescribed orally after meals (not earlier than 1 hour after meals) in the following doses: - adults and children over 15 years of age: 2 tablets 3 times a day; – children from 10 to 14 years old: 1 tablet 3 times a day; – children from 5 to 10 years: 1 tablet 2 times a day; – children from 1 to 5 years: 1 tablet 1 time/day. As a comparison, patients similar in gender, age and clinic were observed who received standard therapy. At the Department of Infectious Diseases of the Russian Medical Academy of Postgraduate Education, research was carried out on the basis of the infectious diseases department of the hospital named after. S.P. Botkin under the guidance of prof. L.V. Pogorelskaya. A total of 156 patients were observed, of which 122 were adult patients (aged 15 to 78 years) and 34 children (aged 1 to 14 years) with BD and acute intestinal diseases [11]. Of particular interest are the clinic's data on the effectiveness of enteric-soluble Sanviritrin tablets for BD in patients with a disease duration of 6 months or more. up to 5 years or more (including against the background of chronic viral infections). In 70% of patients, as a result of using the drug, an improvement in the clinical condition was achieved, diarrhea syndrome was relieved, pain and bloating disappeared, intestinal eubiosis normalized (the content of lactobifidobacteria, coli-bacillus was restored to normal values, Klebsiella and candida in stool cultures disappeared), improvement occurred condition of the intestinal mucosa during sigmoidoscopy, a normalizing effect on the T-cell component of immunity is shown (Table 2). A significant therapeutic effect (normalization of intestinal eubiosis, improvement of the mucous membrane of the rectum and sigmoid colon) under the influence of Sanguiritrin was detected in children with acute dysentery caused by Shigella Sonne type II, and with intestinal dysentery caused by Klebsiella and Candida (Table 3). In children, there was also a significant increase in hemoglobin levels during treatment with Sangviritrin and the manifestation of the immunomodulatory effect of the drug in intestinal diarrhea. It must be said that the use of Sangviritrin for such severe and dangerous infections as salmonellosis and dysentery leads not only to accelerated recovery and relief of clinical symptoms, but also to a more rapid cessation of bacterial excretion of the pathogen compared to standard therapy (Table 4). Similar data were obtained in the intestinal diagnostic department of the children's clinical hospital No. 9 named after. G.N. Speransky when using Sangviritrin against the background of enzyme therapy in 28 children aged 1 to 12 years with acute intestinal infections, which were usually accompanied by a disruption of the normal intestinal microflora (acute infectious gastroenteritis, acute infectious enterocolitis, Sonne's dysentery, salmonellosis). In 90% of cases, a stable therapeutic effect was established (disappearance of vomiting, abdominal pain, etc.), while in 36.6% - with complete normalization of stool. The authors of the study noted that in more severe cases of acute intestinal infections, Sangviritrin tablets, if necessary, can be successfully combined with enzyme and antibacterial therapy, which is also a positive factor (Table 5). At the Department of Skin Diseases of the Russian State Medical University, a study of Sangviritrin enteric tablets was carried out on the basis of the 8th Children's Infectious Diseases Hospital under the leadership of Doctor of Medical Sciences I.V. Khamaganova. The study involved 56 patients with various dermatoses aged from 1.5 to 15 years (Table 6). The study showed that patients with dermatoses (psoriasis, eczema, atopic dermatitis, etc.), complicated by BD and bacterial carriage, achieved not only a clear clinical improvement (regression of rashes, improvement in general condition, absence of fresh rashes), but also normalization of intestinal microflora ( content of epidermal staphylococcus, yeast-like fungi of the genus Candida, bifidobacteria, E. coli with reduced enzymatic activity and hemolyzing E. coli). The data obtained by the clinic indicate the manifestation of an unconditional general resorptive therapeutic effect of enteric soluble tablets of Sangviritrin, expressed in the improvement of the clinical picture of dermatoses, the disappearance of bacterial carriage and bacterial excretion, as well as the normalization of the disturbed microbial flora in BD in pediatric patients with this pathology. The high effectiveness of Sangviritrin tablets in the treatment of purulent-inflammatory diseases complicated by BD and bacterial carriage was also shown in a study of the drug in 110 pediatric patients from 1 to 15 years with pathology of the ENT organs (Children's City Clinical Hospital No. 9 named after G.N. Speransky, 2 –e ENT department). In all patients, the presence of a purulent-inflammatory process was confirmed by bacteriological examination (the presence of pathogenic bacteria in acute and chronic purulent processes and pathogenic fungi in pharyngomycosis). The study revealed that the use of Sangviritrin contributed not only to the positive dynamics of treatment of purulent-inflammatory diseases of the ENT organs in children, but also to the normalization of the microflora accompanying these diseases, prevented the development of convalescent bacterial carriage and had a normalizing effect on the microflora in BD, which often complicates the course of ENT – diseases in pediatric patients (Table 7). The preventive effect of the drug was shown at the Research Institute of Transplantology and Artificial Organs of the Ministry of Health of the Russian Federation when studying the effectiveness of Sangviritrin tablets with the participation of 85 postoperative patients with artificially reduced immunity. The drug was given both for the purpose of preventing complications (17 patients at risk: repeated heart surgery in patients over 60 years old, under conditions of artificial circulation and artificial ventilation - more than 3 days), and for the treatment of infectious complications that arose against the background of ineffective antibiotic therapy in 68 patients (including those accompanied by BD). The study showed the effectiveness of enteric soluble Sanviritrin tablets as a general resorptive antimicrobial agent that prevents the development of convalescent bacterial carriage and BD in postoperative patients with artificially reduced immunity. The presented results of the clinical use of Sangviritrin in the dosage form “enteric tablets” as a general resorptive anti-infective agent indicate the high effectiveness of the drug. With its use, not only an improvement in the clinical picture of the disease, a reduction in recovery time, the disappearance of bacterial carriage and bacterial excretion are observed, but also the elimination of microflora disorders due to dysbacteriosis.

Literature 1. Lesiovskaya E.E., Pastushenkov L.V. Intestinal dysbiosis. // Pharmacotherapy with the basics of herbal medicine. M.: GEOTAR-Med, 2003. pp. 251–266. 2. Vichkanova S.A. Sangviritrin is an antimicrobial drug from plants of the genus Macleaja. In the book: Development and implementation of new methods and means of traditional medicine. Series "Scientific works". T. 2. M., 2001. pp. 103–106. 3. Vichkanova S.A., Tolkachev O.N., Martynova R.G., Arzamastsev E.V. Sangviritrin is a new medicinal herbal preparation with antimicrobial action // Chemical and Pharmaceutical Journal. 1982. T. 16 (12). pp. 107–112. 4. Vichkanova S.A. Sangviritrin. Methodological recommendations for specialists. M., 2001. 21 p. 5. Bykov A.S., Vichkanova S.A., Seleznev A.S., Fateeva T.V., Pashkov E.P. Electron microscopic study of the effect of sanviritrin on microorganisms in in vitro experiments // Antibiotics. 1983. pp. 421–424. 6. Seleznev D.S., Vichkanova S.A., Bykoa A.S., Fateeva T.V., Pashkov E.P. Some aspects of studying the mechanism of action of sanguiritrin on a bacterial cell. In the book: Phytoncides, bacterial plant diseases. Part 1. Uzhgorod, 1985. pp. 101–102. 7. Vichkanova S.A. Features of the use of herbal medicines with antimicrobial and antiviral effects. In the book: Chemistry, technology, medicine. Sat. scientific tr. VNII medic. and aroma. plants. T. 16. pp. 165–174. 8. State register of medicines. T. 1. M., 2009. pp. 389–390. 9. Vichkanova S.A., Kolkhir V.K., Sokolskaya T.A., Okhotnikova V.V., Krutikova N.M., Fateeva T.V., Adgina V.V., Kachalina T.V., Bykov V.A., Val E.V. Medicine – enteric tablets of sanviritrin // Patent for the image. No. 2202341, State. reg. 04/20/2003, prior. 07/06/2001 10. Vichkanova S.A., Khamaganova I.V., Gabrielyan N.I., Pekli F.F., Pogorelskaya L.V., Kolkhir V.K., Krutikova N.M. Clinical studies of sanviritrin as an antimicrobial agent with general resorptive action. In the book: Clinical trials of drugs. International Conference. M., 2002. pp. 48–49. 11. Pogorelskaya L.V., Vichkanova S.A., Bunov S.V. Sangviritrin as an alternative drug for the treatment of acute intestinal infections. In the book: Traditional medicine. 2000. pp. 175–176.

Note!

Description of the drug Sangviritrin solution 0.2% vial. 50ml on this page is a simplified author’s version of the apteka911 website, created on the basis of the instructions for use.
Before purchasing or using the drug, you should consult your doctor and read the manufacturer's original instructions (attached to each package of the drug). Information about the drug is provided for informational purposes only and should not be used as a guide to self-medication. Only a doctor can decide to prescribe the drug, as well as determine the dose and methods of its use.